1. PRODUCT AND COMPANY IDENTIFICATION

Product Name       Minocin Solid Products
Common Name        Not available
Chemical Name      Not applicable
Synonyms           Minocin Tablets, Minocin Capsules, Minocycline Hydrochloride
Product Use        Pharmaceutical product
Classification     Anti-infective Agent
Supplier           Wyeth
                    P.O. Box 8299
                    Philadelphia, PA 19101 USA.
                    Telephone: 1-610-688-4400

Emergency Telephone Number
                    Chemtrec USA, Puerto Rico, Canada 1-800-424-9300
                    Chemtrec International 1-703-527-3887

2. HAZARDS IDENTIFICATION

Emergency Overview
This contains an active pharmaceutical ingredient that can affect body functions; handle with caution.

<table>
<thead>
<tr>
<th>Appearance</th>
<th>Physical State</th>
<th>Odor</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pharmaceutical tablet or capsule</td>
<td>Solid</td>
<td>Not available</td>
</tr>
</tbody>
</table>

Potential Physical Hazards
Powders and solids are presumed to be combustible.

Potential Health Effects

| Eyes       | Not available |
| Skin      | Not available |
| Inhalation| Not available |
| Ingestion | The most common effects may include photosensitivity, central nervous system effects (lightheadedness, dizziness, vertigo), superinfection, nausea, vomiting, intracranial hypertension, and hepatotoxicity. |

May cause cancer. May cause harm to the unborn child. May cause harm to breastfed babies.

Please see Patient Package Insert for further information.

Potential Environmental Effects
There is no known ecological information for this product.
3. COMPOSITION/INFORMATION ON INGREDIENTS

<table>
<thead>
<tr>
<th>Common Name</th>
<th>CAS-No</th>
<th>Composition</th>
</tr>
</thead>
<tbody>
<tr>
<td>Minocycline Hydrochloride</td>
<td>13614-98-7</td>
<td>50 - 100 mg/tablet or capsule</td>
</tr>
<tr>
<td>Inactive Ingredients</td>
<td>Not applicable</td>
<td>.? mg/tablet</td>
</tr>
</tbody>
</table>

4. FIRST AID MEASURES

Eye Contact  
In the case of contact with eyes, rinse immediately with plenty of water for 15 minutes and seek medical advice.

Skin Contact  
Take off contaminated clothing and shoes immediately. Wash off immediately with soap and plenty of water. If skin irritation persists, call a physician.

Inhalation  
Move to fresh air. Artificial respiration and/or oxygen may be necessary. If symptoms persist, call a physician.

Ingestion  
If symptoms persist, call a physician. Do not induce vomiting without medical advice. Never give anything by mouth to an unconscious person.

5. FIRE-FIGHTING MEASURES

Flammable Properties  
Presumed to be a combustible particulate solid.

Extinguishing Media  
Suitable Extinguishing Media: Use water spray, foam, dry chemical or carbon dioxide.

Unsuitable Extinguishing Media: Do NOT use water jet.

Fire Fighting  
Evacuate area and fight fire from a safe distance. Cool closed containers exposed to fire with water spray. In the event of fire and/or explosion do not breathe fumes.

Hazardous Combustion Products  
Carbon oxides, nitrogen oxides.

Protective Equipment and Precautions for Firefighters  
In the event of fire, wear self-contained breathing apparatus and special protective equipment for fire fighters.

6. ACCIDENTAL RELEASE MEASURES

Personal Precautions  
Refer to protective measures listed in Sections 7 and 8.

Environmental Precautions  
Prevent product from entering drains. Local authorities should be advised if a significant spill cannot be contained.

Methods for Containment  
Not available.

Methods for Cleaning up  
Take up mechanically and collect in suitable container for disposal. Clean contaminated surface thoroughly. Avoid formation of dust and aerosols.
7. HANDLING AND STORAGE

Handling
For personal protection see Section 8. Handle in accordance with good industrial hygiene and safety practice. Skin should be washed after contact. Avoid formation of dust and aerosols.

Storage
No special safety precautions required. Keep container tightly closed.

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Common Name
Minocycline Hydrochloride

Exposure Guideline
200 mcg/m³

Engineering Controls
Apply technical measures to comply with the occupational exposure guideline. Local exhaust ventilation is needed for limited open handling or where aerosols may be generated.

Personal Protective Equipment

Eye/face Protection
Provide eye protection based on risk assessment.

Skin Protection
Wear nitrile or latex gloves. Wear protective garment.

Respiratory Protection
Base respirator selection on a risk assessment.

General Hygiene
When using, do not eat, drink or smoke. General industrial hygiene practice. Wash hands before breaks and at the end of workday.

Other
Limit access to only personnel trained in the safe handling of this material. Consult a health and safety professional for specific PPE, respirator, and risk assessment guidance.

9. PHYSICAL AND CHEMICAL PROPERTIES

<table>
<thead>
<tr>
<th>Property</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Appearance</td>
<td>Pharmaceutical tablet or capsule</td>
</tr>
<tr>
<td>Color</td>
<td>Various</td>
</tr>
<tr>
<td>Odor Threshold</td>
<td>Not available</td>
</tr>
<tr>
<td>pH</td>
<td>Not available</td>
</tr>
<tr>
<td>Specific Gravity</td>
<td>Not applicable</td>
</tr>
<tr>
<td>Solubility</td>
<td>Not applicable</td>
</tr>
<tr>
<td>Partition Coefficient</td>
<td>Not available</td>
</tr>
<tr>
<td>(n-octanol/water)</td>
<td></td>
</tr>
<tr>
<td>Boiling Point</td>
<td>Not applicable</td>
</tr>
<tr>
<td>Flash Point</td>
<td>Not applicable</td>
</tr>
<tr>
<td>Melting Point</td>
<td>Not available</td>
</tr>
<tr>
<td>Flammability Limits in Air</td>
<td>Upper Not applicable</td>
</tr>
<tr>
<td>Explosion Limits</td>
<td>Upper Not applicable</td>
</tr>
<tr>
<td>Physical State</td>
<td>Solid</td>
</tr>
<tr>
<td>Odor</td>
<td>Not available</td>
</tr>
<tr>
<td>Water Solubility</td>
<td>Not available</td>
</tr>
<tr>
<td>Evaporation Rate</td>
<td>Not applicable</td>
</tr>
<tr>
<td>Vapor Pressure</td>
<td>Not applicable</td>
</tr>
<tr>
<td>Autoignition Temperature</td>
<td>Not applicable</td>
</tr>
<tr>
<td>Method</td>
<td>None</td>
</tr>
<tr>
<td>Upper</td>
<td>Not applicable</td>
</tr>
<tr>
<td>Lower</td>
<td>Not applicable</td>
</tr>
</tbody>
</table>
10. STABILITY AND REACTIVITY

Chemical Stability
Stable at room temperature.

Conditions to Avoid
No data available

Materials to Avoid
No materials to be especially mentioned.

Hazardous Decomposition Products
None under normal use.

Possibility of Hazardous Reactions
None under normal use.

11. TOXICOLOGICAL INFORMATION

The following effects are based on the Active Pharmaceutical Ingredient.

Acute Toxicity

Minocycline Hydrochloride

<table>
<thead>
<tr>
<th>LD50 Oral</th>
<th>2380 mg/kg rats</th>
</tr>
</thead>
<tbody>
<tr>
<td>1700 mg/kg mice</td>
<td></td>
</tr>
</tbody>
</table>

Acute Dermal Irritation
Not irritating to rabbit skin.

Primary Eye Irritation
Non irritating.

Sensitization
Not a dermal sensitizer in guinea pigs.

Multiple Dose Toxicity

Minocycline Hydrochloride

No Toxicologic Effect

Dose/Species/Study Length:
This compound was tolerated in rats in repeat-dose toxicity studies for 5 months at low dosage; higher doses caused liver toxicity. This compound was tolerated in dogs in repeat-dose toxicity studies for 5 months at low dosage; high doses caused blood effects, anorexia, body weight loss, thyroid pigmentation, thyroid hyperplasia, and skeletal discoloration.

Maximum Tolerated Dose (MTD), Oral

Minocycline Hydrochloride

Carcinogenicity
In long-term carcinogenicity studies in rats, dietary administration of this compound revealed an evidence of thyroid tumor production. Thyroid hyperplasia was also found in rats and dogs treated with this compound.

Genetic Toxicity
Not tested; positive results in \textit{in vitro} mammalian cell assays have been reported for related compounds.

Reproductive Toxicity
General reproduction and fertility studies have been conducted and revealed an evidence of impaired fertility in male rats.

Developmental Toxicity
The teratogenic potential of this compound was assessed in the mouse, rat, rabbit, dog, and monkey and revealed an evidence of adverse effects on skeletal development at maternally toxic doses. This compound crosses the placenta and may cause fetal harm.

Minocycline Hydrochloride

Target Organ(s) of Toxicity
No data available
12. ECOLOGICAL INFORMATION

The following effects are based on the Active Pharmaceutical Ingredient.

Chemical Fate Information Not available

Ecotoxicity Not available

13. DISPOSAL CONSIDERATIONS

Waste Disposal Method Dispose of in accordance with local and national regulations.

14. TRANSPORT INFORMATION

Transport Information This material is not classified as hazardous for transport.

U.S. Department of Transport (DOT) Not regulated
Canadian Transport of Dangerous Goods (TDG) Not regulated
International Civil Aviation Organization (ICAO) Not regulated
International Air Transport Association (IATA) Not regulated
International Maritime Dangerous Goods (IMDG)/International Maritime Organization (IMO) Not regulated
Transport of Dangerous Goods by Rail (RID) Not regulated
Transport of Dangerous Goods by Road (ADR) Not regulated
Transportation of Dangerous Goods via Inland Waterways (ADN) Not regulated

15. REGULATORY INFORMATION

USA

Federal Regulations

OSHA Regulatory Status
This material is not considered hazardous by the OSHA Hazard Communication Standard (29 CFR 1910.1200)

SARA 313
Section 313 of Title III of the Superfund Amendments and Reauthorization Act of 1986 (SARA). This product does not contain any chemicals which are subject to the reporting requirements of the Act and Title 40n of the Code of Federal Regulations, Part 372.

SARA 311/312 Hazardous Categorization

<table>
<thead>
<tr>
<th>Hazard Category</th>
<th>Classification</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acute Health Hazard</td>
<td>No</td>
</tr>
<tr>
<td>Chronic Health Hazard</td>
<td>Yes</td>
</tr>
<tr>
<td>Fire Hazard</td>
<td>No</td>
</tr>
<tr>
<td>Sudden Release of Pressure Hazard</td>
<td>No</td>
</tr>
<tr>
<td>Reactive Hazard</td>
<td>No</td>
</tr>
</tbody>
</table>
This product does not contain any HAPs.

**State Regulations**

**California Proposition 65**
Listed on Proposition 65 as Developmental.

**Canada**
Not classified

**WHMIS Hazard Class**
Not determined

**European Union**
In accordance with EC directives or respective national laws, the product does not need to be classified nor labeled.

### 16. OTHER INFORMATION

**Prepared By**
Wyeth Department of Environment, Health & Safety

**Format**
This MSDS was prepared in accordance with ANSI Z400.1-2004.

**List of References**
See Patient Package Insert for more information.

**Revision Summary**
Administrative

Disclaimer:
The information, data, recommendations, and suggestions appearing in this material safety data sheet (MSDS) and/or in materials regarding our active pharmaceutical ingredients (APIs) or products are based upon tests and data believed to be reliable as of the date of publication. NO REPRESENTATIONS OR WARRANTIES, EITHER EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION ANY WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, OR ANY OTHER WARRANTY IS MADE WITH REGARD TO THE INFORMATION PROVIDED IN THE MSDS, REGARDING THE API, OR THE PRODUCT TO WHICH THE INFORMATION PERTAINS. Accordingly, Wyeth will not be responsible for any damages resulting from use of, or reliance upon, this information as conditions of use are beyond our control. Users are responsible for assuring the safety of their workers and safe operating conditions, and for determining whether the API or product is suitable for their particular purposes. Users shall assume all risks of their use, handling, and disposal of the API and/or product in accordance with all appropriate and applicable regulations. This information relates only to the API or product designated herein, and does not relate to its use in combination with any other API, material, product, or process. No permission is granted for the use of any API or product in a manner that might infringe on existing patents.

End of MSDS